Bitcoin set for a rebound that could stretch toward $100000, BTIG says
DUBLIN - Morgan Stanley & Co. LLC disclosed Tuesday it traded shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL) in its capacity as an exempt principal trader with recognized intermediary status.
According to a regulatory filing with the Irish Takeover Panel under Rule 38.5(a), Morgan Stanley purchased 183,278 ordinary shares of Avadel Pharmaceuticals on November 24, 2025, at prices ranging from $22.86 to $23.14 per share.
The filing also revealed that Morgan Stanley sold 187,242 Avadel shares on the same day, with prices between $22.85 and $23.15 per share.
The disclosure was made in compliance with the Irish Takeover Panel Act requirements for connected exempt principal traders dealing in a client-serving capacity. The filing indicated that Morgan Stanley is connected to Avadel Pharmaceuticals in relation to an unspecified offer.
No cash-settled derivative transactions, stock-settled derivative transactions, or other dealings were reported in the disclosure. The filing also confirmed there were no indemnity arrangements or agreements relating to options or derivatives.
The information was submitted to the Regulatory Information Service as required under Rule 38 of the Irish Takeover Rules, based on the company’s press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.